ArticleApplied and environmental microbiology2020
Engineering Bacillus subtilis as a Versatile and Stable Platform for Production of Nanobodies.
Article in Applied and environmental microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 28 citations in OpenAlex.
- The landscape of antibody production systems: recombinant expression for research, diagnostics and therapy.Frontiers in bioengineering and biotechnology · 2026Review
- Repurposing the bacterial surface display technology for drug delivery.Advanced drug delivery reviews · 2025Review
- Degradable living plastics programmed by engineered spores.Nature chemical biology · 2025Article
- Sortase-mediated surface display of a chimeric immunogen on Bacillus subtilis: a chicken necrotic enteritis vaccine candidate.Microbial cell factories · 2025Article
- Toward Antibody Production in Genome-MinimizedACS synthetic biology · 2025Article
- Neutralizing Nanobodies against Venoms fromToxins · 2024Article
- Camel-Derived Nanobodies as Potent Inhibitors of New Delhi Metallo-β-Lactamase-1 Enzyme.Molecules (Basel, Switzerland) · 2024Article
- Anti-CTLA-4 nanobody as a promising approach in cancer immunotherapy.Cell death & disease · 2024Review
- Advances in bacteria-based drug delivery systems for anti-tumor therapy.Clinical & translational immunology · 2024Review
- Let There Be Light: Genome Reduction EnablesACS synthetic biology · 2023Article
- On-demand biomanufacturing through synthetic biology approach.Materials today. Bio · 2023Article
- Promoted Spore Formation ofIndian journal of microbiology · 2022Article
- Generation of Multivalent Nanobody-Based Proteins with Improved Neutralization of Long α-Neurotoxins from Elapid Snakes.Bioconjugate chemistry · 2022Article
- Mechanisms and Applications of Bacterial Sporulation and Germination in the Intestine.International journal of molecular sciences · 2022Review
- Nanobody-Functionalized Cellulose for Capturing SARS-CoV-2.Applied and environmental microbiology · 2022Article
- The multifunctionality of expression systems inExperimental biology and medicine (Maywood, N.J.) · 2021Review
- Applications of Bacillus subtilis Spores in Biotechnology and Advanced Materials.Applied and environmental microbiology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is a growing need for a highly stable system to allow the production of biologics for diagnoses and therapeutic interventions on demand that could be used in extreme environments. Among the variety of biologics, nanobodies (Nbs) derived from single-chain variable antibody fragments from camelids have attracted great attention in recent years due to their small size and great stability with translational potentials in whole-body imaging and the development of new drugs. Intracellular expression using the bacterium
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.